Following positive clinical-trial findings, shares of Milestone Pharmaceuticals Inc. (NASD: MIST) were up 33.92% to trade at $11.37 in pre-market at the last check. MIST stock ended Friday’s session down -5.14% with 0.13 million shares changing hands.
What was shared by MIST?
In patients with paroxysmal supraventricular tachycardia, Milestone Pharmaceuticals (MIST) today reported encouraging topline effectiveness and safety data from the Phase 3 RAPID clinical trial of etripamil, the Company’s experimental calcium channel blocker (PSVT).
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
- 706 individuals were included in the RAPID study, which was multi-center, randomized, double-blind, and placebo-controlled.
- Without any kind of medical supervision, patients were randomized 1:1 to receive either an etripamil nasal spray or a placebo.
- Patients who did not experience symptom alleviation after 10 minutes were instructed to self-administer a repeat dosage of the study medicine in order to optimize the potential therapeutic impact of etripamil.
- Patients using etripamil showed a very statistically significant and clinically significant improvement in time to PSVT conversion compared to placebo, achieving the primary goal of the RAPID study.
- When etripamil was used instead of a placebo, a statistically substantially higher percentage of patients converted after 30 minutes, according to a Kaplan Meier analysis.
- PSVT is a sporadic, disruptive burden on patients, and the only available therapies are expensive, uncomfortable acute care settings.
- The RAPID trial’s results showed that etripamil-treated patients converted to normal sinus rhythm considerably more frequently than placebo-treated patients, without incurring major adverse effects and without the need for medical care.
- These findings suggest the possibility that etripamil will provide patients with a clinically significant benefit and serve as a crucial and beneficial tool for their doctors.
- Overall, mild (68%) to moderate (31%%) RTEAEs were noted for the majority of patients.
- No major adverse events (AEs) connected to etripamil were recorded.
- More than 1,600 different patients have now received etripamil dosages of less than 70 mg as a consequence of the Company’s entire PSVT clinical study.
What conclusions has MIST drawn from the data?
In the Etripamil clinical trial, Milestone Pharmaceuticals (MIST) observed a statistically significant decrease in the use of extra medical treatments as well as a statistically significant decrease in visits to the emergency room, according to analyses of pooled data from the NODE-301 and RAPID trials. MIST’s complete findings of Phase 3 RAPID clinical trial are anticipated to be presented at a subsequent medical symposium and submitted for publication in a peer-reviewed journal.
